OBJECTIVE: Genomewide association studies have consistently found variants in fibroblast growth factor receptor 2 (FGFR2) to be associated with breast cancer. Recent reports suggest that postmenopausal hormone therapy (HT) use may modify the association between single nucleotide polymorphisms (SNPs) in FGFR2 and breast cancer risk. We assessed the hypothesis that the association between rs1219648 (FGFR2) SNP and breast cancer risk is modified by postmenopausal HT use in a population-based case-control study. METHODS: We evaluated rs1219648 SNP for an association with breast cancer risk using data obtained from 869 postmenopausal breast cancer cases diagnosed between 1995 and 2000 and from 808 postmenopausal community controls who participated in a study conducted in three US states. Detailed postmenopausal HT information was collected through a structured telephone interview, and DNA samples were collected by mail using an established mouthwash protocol. Odds ratios and 95% confidence intervals (CIs) were calculated using logistic regression models adjusted for age and state of residence. RESULTS: We observed a significant association between rs1219648 and breast cancer risk (per-allele odds ratio, 1.22; 95% CI, 1.06-1.41; P = 0.007), which did not vary significantly by ever use of estrogen plus progestogen therapy (interaction P = 0.48). There was stronger evidence of an interaction between ever use of estrogen-only HT and increasing number of rs1219648 risk alleles to increase breast cancer risk (interaction P = 0.08). CONCLUSIONS: Our results are consistent with a risk association with FGFR2 but provide limited support for interaction with HT use. The study raises the possibility that the FGFR2 rs1219648 variant is more strongly associated with risk in estrogen-only hormone users, although this observation needs to be examined in larger studies.
OBJECTIVE: Genomewide association studies have consistently found variants in fibroblast growth factor receptor 2 (FGFR2) to be associated with breast cancer. Recent reports suggest that postmenopausal hormone therapy (HT) use may modify the association between single nucleotide polymorphisms (SNPs) in FGFR2 and breast cancer risk. We assessed the hypothesis that the association between rs1219648 (FGFR2) SNP and breast cancer risk is modified by postmenopausal HT use in a population-based case-control study. METHODS: We evaluated rs1219648 SNP for an association with breast cancer risk using data obtained from 869 postmenopausal breast cancer cases diagnosed between 1995 and 2000 and from 808 postmenopausal community controls who participated in a study conducted in three US states. Detailed postmenopausal HT information was collected through a structured telephone interview, and DNA samples were collected by mail using an established mouthwash protocol. Odds ratios and 95% confidence intervals (CIs) were calculated using logistic regression models adjusted for age and state of residence. RESULTS: We observed a significant association between rs1219648 and breast cancer risk (per-allele odds ratio, 1.22; 95% CI, 1.06-1.41; P = 0.007), which did not vary significantly by ever use of estrogen plus progestogen therapy (interaction P = 0.48). There was stronger evidence of an interaction between ever use of estrogen-only HT and increasing number of rs1219648 risk alleles to increase breast cancer risk (interaction P = 0.08). CONCLUSIONS: Our results are consistent with a risk association with FGFR2 but provide limited support for interaction with HT use. The study raises the possibility that the FGFR2rs1219648 variant is more strongly associated with risk in estrogen-only hormone users, although this observation needs to be examined in larger studies.
Authors: Miriam S Udler; Kerstin B Meyer; Karen A Pooley; Eric Karlins; Jeffery P Struewing; Jinghui Zhang; David R Doody; Stewart MacArthur; Jonathan Tyrer; Paul D Pharoah; Robert Luben; Leslie Bernstein; Laurence N Kolonel; Brian E Henderson; Loic Le Marchand; Giske Ursin; Michael F Press; Paul Brennan; Suleeporn Sangrajrang; Valerie Gaborieau; Fabrice Odefrey; Chen-Yang Shen; Pei-Ei Wu; Hui-Chun Wang; Daehee Kang; Keun-Young Yoo; Dong-Young Noh; Sei-Hyun Ahn; Bruce A J Ponder; Christopher A Haiman; Kathleen E Malone; Alison M Dunning; Elaine A Ostrander; Douglas F Easton Journal: Hum Mol Genet Date: 2009-02-17 Impact factor: 6.150
Authors: Leon Raskin; Mila Pinchev; Chana Arad; Flavio Lejbkowicz; Ada Tamir; Hedy S Rennert; Gad Rennert; Stephen B Gruber Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-05 Impact factor: 4.254
Authors: M García-Closas; K M Egan; J Abruzzo; P A Newcomb; L Titus-Ernstoff; T Franklin; P K Bender; J C Beck; L Le Marchand; A Lum; M Alavanja; R B Hayes; J Rutter; K Buetow; L A Brinton; N Rothman Journal: Cancer Epidemiol Biomarkers Prev Date: 2001-06 Impact factor: 4.254
Authors: Ruth C Travis; Gillian K Reeves; Jane Green; Diana Bull; Sarah J Tipper; Krys Baker; Valerie Beral; Richard Peto; John Bell; Diana Zelenika; Mark Lathrop Journal: Lancet Date: 2010-06-03 Impact factor: 79.321
Authors: Ross L Prentice; Ying Huang; David A Hinds; Ulrike Peters; Mary Pettinger; David R Cox; Erica Beilharz; Rowan T Chlebowski; Jacques E Rossouw; Bette Caan; Dennis G Ballinger Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-10-27 Impact factor: 4.254
Authors: Timothy R Rebbeck; Angela DeMichele; Teo V Tran; Saarene Panossian; Greta R Bunin; Andrea B Troxel; Brian L Strom Journal: Carcinogenesis Date: 2008-11-20 Impact factor: 4.944
Authors: Montserrat Garcia-Closas; Per Hall; Heli Nevanlinna; Karen Pooley; Jonathan Morrison; Douglas A Richesson; Stig E Bojesen; Børge G Nordestgaard; Christen K Axelsson; Jose I Arias; Roger L Milne; Gloria Ribas; Anna González-Neira; Javier Benítez; Pilar Zamora; Hiltrud Brauch; Christina Justenhoven; Ute Hamann; Yon-Dschun Ko; Thomas Bruening; Susanne Haas; Thilo Dörk; Peter Schürmann; Peter Hillemanns; Natalia Bogdanova; Michael Bremer; Johann Hinrich Karstens; Rainer Fagerholm; Kirsimari Aaltonen; Kristiina Aittomäki; Karl von Smitten; Carl Blomqvist; Arto Mannermaa; Matti Uusitupa; Matti Eskelinen; Maria Tengström; Veli-Matti Kosma; Vesa Kataja; Georgia Chenevix-Trench; Amanda B Spurdle; Jonathan Beesley; Xiaoqing Chen; Peter Devilee; Christi J van Asperen; Catharina E Jacobi; Rob A E M Tollenaar; Petra E A Huijts; Jan G M Klijn; Jenny Chang-Claude; Silke Kropp; Tracy Slanger; Dieter Flesch-Janys; Elke Mutschelknauss; Ramona Salazar; Shan Wang-Gohrke; Fergus Couch; Ellen L Goode; Janet E Olson; Celine Vachon; Zachary S Fredericksen; Graham G Giles; Laura Baglietto; Gianluca Severi; John L Hopper; Dallas R English; Melissa C Southey; Christopher A Haiman; Brian E Henderson; Laurence N Kolonel; Loic Le Marchand; Daniel O Stram; David J Hunter; Susan E Hankinson; David G Cox; Rulla Tamimi; Peter Kraft; Mark E Sherman; Stephen J Chanock; Jolanta Lissowska; Louise A Brinton; Beata Peplonska; Jan G M Klijn; Maartje J Hooning; Han Meijers-Heijboer; J Margriet Collee; Ans van den Ouweland; Andre G Uitterlinden; Jianjun Liu; Low Yen Lin; Li Yuqing; Keith Humphreys; Kamila Czene; Angela Cox; Sabapathy P Balasubramanian; Simon S Cross; Malcolm W R Reed; Fiona Blows; Kristy Driver; Alison Dunning; Jonathan Tyrer; Bruce A J Ponder; Suleeporn Sangrajrang; Paul Brennan; James McKay; Fabrice Odefrey; Valerie Gabrieau; Alice Sigurdson; Michele Doody; Jeffrey P Struewing; Bruce Alexander; Douglas F Easton; Paul D Pharoah Journal: PLoS Genet Date: 2008-04-25 Impact factor: 5.917
Authors: Kerstin B Meyer; Ana-Teresa Maia; Martin O'Reilly; Andrew E Teschendorff; Suet-Feung Chin; Carlos Caldas; Bruce A J Ponder Journal: PLoS Biol Date: 2008-05-06 Impact factor: 8.029
Authors: Thomas M Campbell; Mauro A A Castro; Ines de Santiago; Michael N C Fletcher; Silvia Halim; Radhika Prathalingam; Bruce A J Ponder; Kerstin B Meyer Journal: Carcinogenesis Date: 2016-05-28 Impact factor: 4.944
Authors: Anja Rudolph; Rebecca Hein; Sara Lindström; Lars Beckmann; Sabine Behrens; Jianjun Liu; Hugues Aschard; Manjeet K Bolla; Jean Wang; Thérèse Truong; Emilie Cordina-Duverger; Florence Menegaux; Thomas Brüning; Volker Harth; Gianluca Severi; Laura Baglietto; Melissa Southey; Stephen J Chanock; Jolanta Lissowska; Jonine D Figueroa; Mikael Eriksson; Keith Humpreys; Hatef Darabi; Janet E Olson; Kristen N Stevens; Celine M Vachon; Julia A Knight; Gord Glendon; Anna Marie Mulligan; Alan Ashworth; Nicholas Orr; Minouk Schoemaker; Penny M Webb; Pascal Guénel; Hiltrud Brauch; Graham Giles; Montserrat García-Closas; Kamila Czene; Georgia Chenevix-Trench; Fergus J Couch; Irene L Andrulis; Anthony Swerdlow; David J Hunter; Dieter Flesch-Janys; Douglas F Easton; Per Hall; Heli Nevanlinna; Peter Kraft; Jenny Chang-Claude Journal: Endocr Relat Cancer Date: 2013-11-04 Impact factor: 5.678